![Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials - The Lancet Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials - The Lancet](https://www.thelancet.com/cms/attachment/33d5ff9b-9a8f-4dec-a982-ee5817b5b461/gr1_lrg.jpg)
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials - The Lancet
![Cancers | Free Full-Text | Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer Cancers | Free Full-Text | Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer](https://www.mdpi.com/cancers/cancers-14-01959/article_deploy/html/images/cancers-14-01959-g006.png)
Cancers | Free Full-Text | Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer
![Cancers | Free Full-Text | Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Cancers | Free Full-Text | Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes](https://www.mdpi.com/cancers/cancers-14-00864/article_deploy/html/images/cancers-14-00864-g001-550.jpg)
Cancers | Free Full-Text | Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes
![Analogues de la LH-RH dans le traitement hormonal adjuvant dans les cancers du sein localisés de la femme pré-ménopausée : la fin d'une controverse pour de nouvelles recommandations ? - ScienceDirect Analogues de la LH-RH dans le traitement hormonal adjuvant dans les cancers du sein localisés de la femme pré-ménopausée : la fin d'une controverse pour de nouvelles recommandations ? - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S000745511930089X-gr1.jpg)
Analogues de la LH-RH dans le traitement hormonal adjuvant dans les cancers du sein localisés de la femme pré-ménopausée : la fin d'une controverse pour de nouvelles recommandations ? - ScienceDirect
![Types of NAT and surgical treatment in the examined population (LHRH:... | Download Scientific Diagram Types of NAT and surgical treatment in the examined population (LHRH:... | Download Scientific Diagram](https://www.researchgate.net/publication/343092651/figure/tbl1/AS:917226081251328@1595695147007/Types-of-NAT-and-surgical-treatment-in-the-examined-population-LHRH-Luteinizing.png)
Types of NAT and surgical treatment in the examined population (LHRH:... | Download Scientific Diagram
![IJMS | Free Full-Text | Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions IJMS | Free Full-Text | Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions](https://www.mdpi.com/ijms/ijms-21-09511/article_deploy/html/images/ijms-21-09511-g002.png)
IJMS | Free Full-Text | Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions
![Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone | Nature Reviews Endocrinology Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone | Nature Reviews Endocrinology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fncpendmet0399/MediaObjects/41574_2007_Article_BFncpendmet0399_Fig1_HTML.jpg)
Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone | Nature Reviews Endocrinology
![Frontiers | Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers Frontiers | Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers](https://www.frontiersin.org/files/Articles/1143261/fendo-14-1143261-HTML/image_m/fendo-14-1143261-g001.jpg)
Frontiers | Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers
![Evolution of breast cancer treatments: current options and quality-of-life considerations - ScienceDirect Evolution of breast cancer treatments: current options and quality-of-life considerations - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1462388904001000-gr1.jpg)
Evolution of breast cancer treatments: current options and quality-of-life considerations - ScienceDirect
![Frontiers | Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women Frontiers | Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women](https://www.frontiersin.org/files/Articles/700722/fonc-11-700722-HTML-r1/image_m/fonc-11-700722-g001.jpg)
Frontiers | Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
Full article: Preliminary clinical application of an aromatase inhibitor and a gonadotropin-releasing hormone agonist combination for inoperable endometrial cancer patients with comorbidities: case report and literature review
![Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer | Nature Reviews Urology Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer | Nature Reviews Urology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41585-021-00514-9/MediaObjects/41585_2021_514_Fig1_HTML.png)
Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer | Nature Reviews Urology
![Luteinizing hormone-releasing hormone (LHRH) analogues ± mode of action. | Download Scientific Diagram Luteinizing hormone-releasing hormone (LHRH) analogues ± mode of action. | Download Scientific Diagram](https://www.researchgate.net/profile/Joerg-Engel/publication/12348659/figure/fig1/AS:277263951122432@1443116285246/Luteinizing-hormone-releasing-hormone-LHRH-analogues-mode-of-action_Q320.jpg)
Luteinizing hormone-releasing hormone (LHRH) analogues ± mode of action. | Download Scientific Diagram
![Luteinizing hormone-releasing hormone (LHRH) analogues ± mode of action. | Download Scientific Diagram Luteinizing hormone-releasing hormone (LHRH) analogues ± mode of action. | Download Scientific Diagram](https://www.researchgate.net/publication/12348659/figure/fig1/AS:277263951122432@1443116285246/Luteinizing-hormone-releasing-hormone-LHRH-analogues-mode-of-action.png)
Luteinizing hormone-releasing hormone (LHRH) analogues ± mode of action. | Download Scientific Diagram
![IJMS | Free Full-Text | Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions IJMS | Free Full-Text | Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions](https://pub.mdpi-res.com/ijms/ijms-21-09511/article_deploy/html/images/ijms-21-09511-g001.png?1621232659)
IJMS | Free Full-Text | Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions
![Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing Hormone-Releasing Hormone (99mTc/Re-Acdien-LHRH) Conjugates for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH Receptor | ACS Omega Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing Hormone-Releasing Hormone (99mTc/Re-Acdien-LHRH) Conjugates for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH Receptor | ACS Omega](https://pubs.acs.org/cms/10.1021/acsomega.0c03991/asset/images/large/ao0c03991_0008.jpeg)